These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
14. A challenging road to diagnosing transthyretin cardiac amyloidosis and using technetium-99m pyrophosphate bone scintigraphy in nuclear cardiology - A case report. Kavita A; Abdul Onny MA; Suppiah S; Abdul Aziz AF; Hashim H; Raja Shariff RE; Ng CS Med J Malaysia; 2021 Sep; 76(5):762-767. PubMed ID: 34508392 [TBL] [Abstract][Full Text] [Related]
17. Bone scintigraphy with (99m)technetium-hydroxymethylene diphosphonate allows early diagnosis of cardiac involvement in patients with transthyretin-derived systemic amyloidosis. Glaudemans AW; van Rheenen RW; van den Berg MP; Noordzij W; Koole M; Blokzijl H; Dierckx RA; Slart RH; Hazenberg BP Amyloid; 2014 Mar; 21(1):35-44. PubMed ID: 24455993 [TBL] [Abstract][Full Text] [Related]
18. Diagnostic accuracy of bone scintigraphy in the assessment of cardiac transthyretin-related amyloidosis: a bivariate meta-analysis. Treglia G; Glaudemans AWJM; Bertagna F; Hazenberg BPC; Erba PA; Giubbini R; Ceriani L; Prior JO; Giovanella L; Slart RHJA Eur J Nucl Med Mol Imaging; 2018 Oct; 45(11):1945-1955. PubMed ID: 29687207 [TBL] [Abstract][Full Text] [Related]
19. Bone scintigraphy imaging and transthyretin-related (ATTR) cardiac amyloidosis: New tricks from an old tool? Duran JM; Borges-Neto S J Nucl Cardiol; 2023 Feb; 30(1):368-370. PubMed ID: 35869405 [No Abstract] [Full Text] [Related]
20. Safety and efficacy of a TTR specific antisense oligonucleotide in patients with transthyretin amyloid cardiomyopathy. Benson MD; Dasgupta NR; Rissing SM; Smith J; Feigenbaum H Amyloid; 2017 Dec; 24(4):219-225. PubMed ID: 28906150 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]